Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …

Importance Treatment options for COVID-19 are warranted irrespective of the presence of
risk factors for severe disease. Objective To assess the efficacy and safety of ensitrelvir in …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Summary Background SIM0417 (SSD8432) is an orally administered coronavirus main
proteinase (3CL pro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to …

Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

Background This phase 2b part of a randomized phase 2/3 study assessed the efficacy and
safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background: Limited treatment options exist for patients with mild-to-moderate coronavirus
disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a …